Skip to main content
news)

NEWS

Media Contacts:

United States

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Seqirus news releases

Seqirus news releases

Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases
20 Apr 2021

Company announces the publication of new real-world evidence on effectiveness of the MF59® adjuvanted, trivalent influenza vaccine (aTIV).

COVID-19 Update
02 Apr 2020

Safeguarding our people and communities remains our top priority.

Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
24 Feb 2020

Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.1

Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
03 Feb 2020

Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.

Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
26 Sep 2019

Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health. The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.

Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
31 Aug 2019

Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.1

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
30 Aug 2019

Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from clinical studies demonstrating the ability of a MF59® adjuvanted influenza vaccine to increase immune responses when used in both seasonal and pandemic influenza vaccines.

Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines
15 Jul 2019

This news release is intended for business and trade media only.